NovoCure Limited

NVCR Healthcare Medical Devices

NovoCure Limited’s revenue for fiscal 2025 (year ended December 2025) was $655.4 million, up 8.28% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 63.9%, free cash flow grew 105.7% and total debt rose 100.7%, each against the same quarter a year earlier.

14.07 0.34 −2.36%
Market cap
$1.7B
P/E
0.0×
Fwd P/E
−10.8×
Dividend yield
—
F-score
4/9
Altman Z
0.43
Beneish M
−2.12
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 4 3 3
ROE
(50.60%) (38.89%) (49.96%) (43.22%)
ROA
(13.75%) (13.32%) (16.99%) (14.56%)
ROIC
0.00% (123.24%) (92.52%) (115.56%)
Return on Tangible Assets
(33.88%) (26.04%) (33.69%) (28.58%)
Average Days of Receivables
70.88 82.49 79.24 76.12
Free Cash Flow per Share
(0.58) (0.68) (0.42) (0.22)
Free Cash Flow
(65.17) (75.68) (48.07) (25.43)
Other line items

Show all line items

Columns are period end dates